Abstract

Abstract Introduction Stereotactic arrhythmia radioablation (STAR) has been recently introduced for the management of ventricular tachycardia (VT) refractory to antiarrhythmic drugs (AADs) and catheter ablation (CA). VT recurrences were recently reported after STAR but the mechanisms remain poorly known. Purpose We analyzed VT recurrences after STAR for refractory VT in order to assess the characteristics and delivered dose at sites of VT relapse. Methods From 09.2017 to 01.2020, 12 consecutive patients (pts) (66±8y, LVEF 40±14%) suffering from refractory VT were enrolled. The underlying cardiopathy was ischemic in 3, inflammatory in 3 and idiopathic in 6 pts. Nine (75%) out of 12 pts had a history of at least 1 electrical storm. Before STAR, an invasive electro-anatomical mapping (Carto3) of the VT substrate (VT-sub) was performed. A mean dose of 22±2Gy was delivered to the VT-sub using the Cyberknife® system. Results The ablation volume was 24±7cc and involved the basal interventricular septum (IVS) in 10 (83%) pts. During the first 6 months after STAR, VT burden decreased by 93% (mean value, from 640 to 46 VT/semester). After a median follow-up of 32±11 months, 10/12 (83%) developed ≥1 recurrence as a sustained VT and underwent a redo CA. Two (17%) pts presented 2 distinct VT recurrences from clearly different areas. VT recurrence was located at the border zone (BZ) of the treated VT-sub in 6 (50%) cases, involved both the BZ and a larger substrate in 2 (17%) cases, and occurred remote from the VT-sub in 4 (33%) cases (see Table 1). The dose delivered at sites of VT recurrence was 8.4±8.6 Gy with a large heterogeneity ranging from 0.11 to 28.37 Gy, for some pts due to dose constraints near critical structures (coronary arteries). Voltage mapping showed a small but significant reduction in both unipolar and bipolar EGM voltage in the irradiated area after STAR (before vs after, Bipolar: 1.8±1.2 vs 1.1±1.2 mV and Unipolar: 4.4±2.0 vs 3.4±2.3 mV, p=0.02 and 0.01 respectively). Importantly no pts developed a high-grade AV block after STAR despite IVS irradiation. Conclusion STAR appears to be an efficient tool for the management of refractory VT, leading to a strong VT burden reduction and no new high-grade AV block. Recurrences were nevertheless common, often at the border zone of the irradiated volume. Funding Acknowledgement Type of funding sources: Public hospital(s). Main funding source(s): CHUV

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.